Abstract
Newer treatments of advanced human cancer increasingly rely on combinations of drugs that have quite different actions yet unexpectedly potentiate each others effects. Recent research in stem cell biology suggests a model for tumors in which tumor growth is governed by the generation of cells from tumor cell niches rather than from the population as a whole. Each niche contains a population of tumor stem cells supported by a closely associated vascular bed comprising mesenchyme-derived cells and an extracellular matrix. Division of tumor stem cells is asymmetric in the sense that some daughter cells are always retained within the niche while others leave the niche to proliferate further and eventually die. One important potential difference between normal and tumor stem cell niches is that while most normal stem cells are in a non-proliferating or Go-state, tumor stem cells are continuously in cycle. Combinations of cytotoxic drugs and antagonists of survival factors to reduce the stem cell population may require the addition of vascular disrupting agents to compromise the function of the tumor cell niche. As well as providing opportunities for new drug discovery, this model of tumor growth also presents challenges as to how the contributions of individual drugs in a combination might be assessed in individual patients.
Keywords: Stem cells, stroma, niche, cytokinetics, survival factors, cytotoxic drugs, signal transduction inhibitors, vascular disrupting agents
Recent Patents on Anti-Cancer Drug Discovery
Title: Tumor Stem Cell Niches: A New Functional Framework for the Action of Anticancer Drugs
Volume: 1 Issue: 1
Author(s): Bruce C. Baguley
Affiliation:
Keywords: Stem cells, stroma, niche, cytokinetics, survival factors, cytotoxic drugs, signal transduction inhibitors, vascular disrupting agents
Abstract: Newer treatments of advanced human cancer increasingly rely on combinations of drugs that have quite different actions yet unexpectedly potentiate each others effects. Recent research in stem cell biology suggests a model for tumors in which tumor growth is governed by the generation of cells from tumor cell niches rather than from the population as a whole. Each niche contains a population of tumor stem cells supported by a closely associated vascular bed comprising mesenchyme-derived cells and an extracellular matrix. Division of tumor stem cells is asymmetric in the sense that some daughter cells are always retained within the niche while others leave the niche to proliferate further and eventually die. One important potential difference between normal and tumor stem cell niches is that while most normal stem cells are in a non-proliferating or Go-state, tumor stem cells are continuously in cycle. Combinations of cytotoxic drugs and antagonists of survival factors to reduce the stem cell population may require the addition of vascular disrupting agents to compromise the function of the tumor cell niche. As well as providing opportunities for new drug discovery, this model of tumor growth also presents challenges as to how the contributions of individual drugs in a combination might be assessed in individual patients.
Export Options
About this article
Cite this article as:
Baguley C. Bruce, Tumor Stem Cell Niches: A New Functional Framework for the Action of Anticancer Drugs, Recent Patents on Anti-Cancer Drug Discovery 2006; 1 (1) . https://dx.doi.org/10.2174/157489206775246494
DOI https://dx.doi.org/10.2174/157489206775246494 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Use of Cell Lines in the Investigation of Pharmacogenetic Loci
Current Pharmaceutical Design p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design Editorial: Looking Forward to Another Successful Year
Current Cancer Drug Targets Cytotoxic and Antitumoral Activity of N-(9H-purin-6-yl) Benzamide Derivatives and Related Water-soluble Prodrugs
Current Molecular Pharmacology Destabilizing Aneuploidy by Targeting Cell Cycle and Mitotic Checkpoint Proteins in Cancer Cells
Current Drug Targets Anti-Proliferative Effects of Novel Glyco-Lipid-Arsenicals (III) on MCF-7 Human Breast Cancer Cells
Medicinal Chemistry Interferon alpha for Treatment of Chronic Myeloid Leukemia
Current Drug Targets Molecular Foundations for Personalized Therapy in Prostate Cancer
Current Drug Targets Ceramide and Apoptosis: Exploring the Enigmatic Connections between Sphingolipid Metabolism and Programmed Cell Death
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Proteins in Tumors and Targeted Therapeutic Agents for Cancer Patients
Protein & Peptide Letters Use of the Non-Toxic Cryoprotectant Trehalose Enhances Recovery and Function of Fish Embryonic Stem Cells Following Cryogenic Storage
Current Stem Cell Research & Therapy Isoform Characterisation, Heterologous Expression and Functional Analysis of Two Lectins from Vatairea macrocarpa
Protein & Peptide Letters Anti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti-Cancer Therapy
Current Cancer Drug Targets Chemical Genomic and Proteomic Methods for Determining Kinase Inhibitor Selectivity
Combinatorial Chemistry & High Throughput Screening New Treatment Approaches in Acute Myeloid Leukemia: Review of Recent Clinical Studies
Reviews on Recent Clinical Trials Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies
Recent Patents on Anti-Cancer Drug Discovery Translational Gap in Glioma Research
Anti-Cancer Agents in Medicinal Chemistry New Approaches to Target Cancer Stem Cells: Current Scenario
Mini-Reviews in Medicinal Chemistry Dietary Phytochemicals in Chemoprevention of Cancer: An Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Glioma Stem Cell Maintenance: The Role of the Microenvironment
Current Pharmaceutical Design